NASDAQ:FEED Nanovibronix (FEED) Stock Price, News & Analysis $1.01 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.01 +0.00 (+0.20%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Nanovibronix Stock (NASDAQ:FEED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nanovibronix alerts:Sign Up Key Stats Today's Range$0.93▼$1.0650-Day Range$0.93▼$2.6452-Week Range$0.84▼$17.40Volume194,491 shsAverage Volume703,851 shsMarket Capitalization$6.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings. The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves. As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.AI Generated. May Contain Errors. Read More Nanovibronix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreFEED MarketRank™: Nanovibronix scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNanovibronix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNanovibronix has only been the subject of 1 research reports in the past 90 days.Read more about Nanovibronix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nanovibronix is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nanovibronix is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanovibronix has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of Nanovibronix has been sold short.Short Interest Ratio / Days to CoverNanovibronix has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanovibronix has recently decreased by 32.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanovibronix does not currently pay a dividend.Dividend GrowthNanovibronix does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentNanovibronix has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nanovibronix this week, compared to 2 articles on an average week.Search Interest3 people have searched for FEED on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nanovibronix insiders have not sold or bought any company stock.Percentage Held by Insiders1.40% of the stock of Nanovibronix is held by insiders.Percentage Held by Institutions16.39% of the stock of Nanovibronix is held by institutions.Read more about Nanovibronix's insider trading history. Receive FEED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanovibronix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FEED Stock News HeadlinesENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026May 19, 2026 | globenewswire.comFinancial Review: Nanovibronix (NASDAQ:FEED) and MiniMed Group (NASDAQ:MMED)May 18, 2026 | americanbankingnews.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect. | Weiss Ratings (Ad)ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of CareMay 12, 2026 | globenewswire.comENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery TechnologyMay 8, 2026 | globenewswire.comENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 HospitalsMay 7, 2026 | globenewswire.comFEED ENvue Medical, Inc.May 6, 2026 | seekingalpha.comBrazil Potash Awards Front-End Engineering Design (FEED) Contract for Surface Facilities and Infrastructure to Wood and Promon Engenharia, Advancing Bankability of the Autazes ProjectMay 6, 2026 | globenewswire.comSee More Headlines FEED Stock Analysis - Frequently Asked Questions How have FEED shares performed this year? Nanovibronix's stock was trading at $2.30 at the beginning of the year. Since then, FEED stock has decreased by 56.1% and is now trading at $1.01. How were Nanovibronix's earnings last quarter? Nanovibronix, Inc. (NASDAQ:FEED) issued its quarterly earnings data on Monday, May, 18th. The company reported ($6.88) EPS for the quarter. The business had revenue of $0.65 million for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative trailing twelve-month return on equity of 54.25%. How do I buy shares of Nanovibronix? Shares of FEED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/18/2026Today5/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 FEED's financial health is in the Yellow zone, according to TradeSmith. FEED has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEED CIK1326706 WebN/A Phone(914) 233-3004Fax914-376-6111Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($41.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.18 million Net Margins-923.20% Pretax Margin-936.45% Return on Equity-54.25% Return on Assets-43.10% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.74 Sales & Book Value Annual Sales$2.55 million Price / Sales2.41 Cash FlowN/A Price / Cash FlowN/A Book Value$5.26 per share Price / Book0.19Miscellaneous Outstanding Shares6,090,000Free Float6,007,000Market Cap$6.15 million OptionableN/A Beta1.59 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:FEED) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanovibronix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanovibronix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.